We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Dr
Alessandro
Prete
a.prete@bham.ac.uk
Kady
Hutton
ras@uhb.nhs.uk
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Benign neoplasmsMalignant neoplasms of thyroid and other endocrine glands
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Tumours of the adrenal gland are frequent in the general population and are mostly harmless. However, in about one third of cases, they can secrete steroid hormones in excess and be responsible for clinical syndromes associated with cardiovascular and/or metabolic diseases. In the rare situation that these tumours are cancerous (adrenocortical carcinomas, ACC), they tend to be highly aggressive. About half of the patients who had an ACC removed see the tumour come back within 2 years and most die within 5 years from diagnosis.
In this study, we intend to answer to the following important open questions for patients with adrenal tumours:
• Are there any clinical parameters or biological molecules that can clearly distinguish benign from malignant tumours and steroid-producing from clinically indolent ones? May these parameters also predict the clinical outcome of patients with adrenal tumours?
• Follow-up of patients with ACC currently requires frequent scans that are expensive, result in increased radiation exposure and cannot always answer diagnostic questions. Can we identify any other markers that can improve surveillance of these patients?
• No effective treatment exists nowadays for patients with advanced stage ACC. Are there any molecular alterations that can be targeted by new drugs? Our ultimate aim will be to establish and validate easily applicable methods to transfer our diagnostic and prognostic tools into the clinical practice, for an individualised management of patients with adrenal tumours.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
For all cohorts (both baseline and follow-up assessments): o Age <18 years o Any significant disease, disorder or treatment that, in the opinion of the Investigators, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study. For cohorts 2-5: o Past medical history of ACT
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Kady
Hutton
ras@uhb.nhs.uk
Ms
Cristina
Ronchi
C.L.Ronchi@bham.ac.uk
Dr
Alessandro
Prete
a.prete@bham.ac.uk
The study is sponsored by University of Birmingham and funded by THE BRITISH DIABETIC ASSOCIATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49365
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
